Clinical characteristics and biochemical measurements of nine patients with “apparent” heart failure before and after renal percutaneous angioplasty or surgical revascularisation
| Patient, age, sex |
Pretreatment supine BP (mm Hg) (n drugs) |
Supine BP 48 h postintervent (mm Hg) (n drugs) |
Recent supine BP (months postintervent; n drugs) | Baseline serum creatinine (μmol/l) |
Se creatinine 7 d postintervent (μmol/l) |
Se creatinine (μmol/l) (months postintervent) |
Plasma ANF preintervent (pg/ml) |
Plasma ANF (pg/ml) (d postintervent) | Na excr 24 h postintervent (mmol) |
Weight loss in 1 week postintervent (kg) | Angiographic findings in renal arteries |
| 1, 65, F1-150 1-151 | 180/105 (4) | 158/90 (4) | — | 482 | 154 | 125 (24) | — | — | — | 5.2 | Occl right RA; severe left RA stenosis |
| 2, 51, M | 180/106 (3) | 160/100 (3) | 138/87 (38; 3) | 162 | 109 | 129 (38) | — | — | 538 | 6.4 | Occl right RA; severe left RA stenosis |
| 3, 73, M | 194/96 (4) | 125/70 (4) | 176/95 (2; 3) | 172 | 169 | 135 (2) | 133 | 88 (7) | 485 | 5.5 | Occl left RA; severe right RA stenosis |
| 4, 62, F1-150 | 191/94 (3) | 168/90 (3) | 177/86 (23; 2) | 196 | 137 | 159 (23) | 98 | 44 (4) | 560 | 3.2 | Occl left RA; severe right RA stenosis |
| 5, 60, F | 186/95 (4) | 103/68 (4) | 160/99 (4; 1) | 148 | 105 | 78 (3) | — | — | — | 5.1 | Occl left RA; severe right RA stenosis |
| 6, 70, M | 229/92 (3) | 168/60 (3) | 115/71 (23; 2) | 205 | 187 | 112 (23) | 53.2 | 43 (3) | — | 3.1 | Bilateral severe RA stenoses |
| 7, 77, F | 220/84 (3) | 163/64 (3) | 162/71 (24; 3) | 102 | 102 | 116 (21) | 250 | 21 (6) | 316 | 1.8 | Bilateral severe RA stenoses |
| 8, 76, M | 162/95 (2) | 141/61 (2) | 128/86 (32; 2) | 124 | 116 | 117 (33) | 86.9 | 46.6 (4) | — | 2.2 | Bilateral severe RA stenoses |
| 9, 72, M | 174/76 (2) | 163/69 (2) | 151/69 (36; 2) | 213 | 185 | 175 (36) | 98.4 | 46.6 (4) | — | 1.5 | Bilateral severe RA stenoses |
| Mean (SEM) | 191/94 (7/3) | 150/75 (8/5) | 151/83 (8/4) | 200 (37) | 140 (11) | 127 (9) | 120 (28) | 48 (9) | — | 3.8 (0.6) |